hepatitis C

Why Gilead's new hepatitis C drug is a game changer — price and all
Bizjournals.com
Tue, 06/28/16 - 05:37 pm
Gilead Sciences
hepatitis C
drug pricing
Epclusa
FDA halts testing of Regulus' Hep C drug, sending shares into tailspin
BioPharma Dive
Tue, 06/28/16 - 11:04 am
FDA
Regulus
hepatitis C
clinical trials
RG-101
Can Gilead Sciences Rebound in the Second Half of 2016?
Motley Fool
Sat, 06/25/16 - 01:44 pm
Gilead Sciences
hepatitis C
Gilead Sciences: What’s Next in Hepatitis C?
Barron's
Fri, 06/24/16 - 09:14 am
Gilead Sciences
hepatitis C
sof/vel/GS-9857
sof/vel
Gilead Sciences, Inc: Where’s The Biotech Giant Headed?
Bidness, ETC
Wed, 06/22/16 - 10:42 am
Gilead Sciences
HIV
hepatitis C
Gilead Sciences, Inc: Uptick in New HCV Scripts Does Not Signal a Good Quarter
Bidness, ETC
Sat, 06/18/16 - 09:18 am
Gilead Sciences
Harvoni
Sovaldi
hepatitis C
Payer interest grows in outcomes-based drug deals: report
BioPharma Dive
Fri, 06/17/16 - 09:33 pm
hepatitis C
oncology
payers
pay-for-performance
Gilead Sciences: A ‘Strong Uptick’ in New Hepatitis C Prescriptions
Barron's
Fri, 06/17/16 - 12:16 pm
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Will Gilead (GILD) Stock Be Helped by Hepatitis C Drug Patents Case Win?
TheStreet.com
Thu, 06/9/16 - 09:47 am
Gilead Sciences
Merck
patents
hepatitis C
Harvoni
Sovaldi
Gilead won’t have to pay $200 million in patent case because Merck lawyer lied
Stat
Wed, 06/8/16 - 09:38 am
Gilead Sciences
patents
Merck
hepatitis C
Sovaldi
Harvoni
Burden of pricey hepatitis C drugs heaviest in eastern Europe
Yahoo/Reuters
Wed, 06/1/16 - 10:10 am
drug pricing
hepatitis C
Europe
Eastern Europe
Washington Ordered to Cover Hepatitis C Drugs During Lawsuit
Bloomberg
Fri, 05/27/16 - 10:54 pm
hepatitis C
Washington
Medicaid
Harvoni
Sovaldi
Gilead Sciences
Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
Seeking Alpha
Wed, 05/25/16 - 11:31 am
Achillion
ACH-4471
JNJ
hepatitis C
Gilead Sciences: It’s More Than Hepatitis C…But Not Enough More For Now
Barron's
Sun, 05/22/16 - 11:39 am
hepatitis C
Gilead Sciences
HIV
Genvoya
Stribild
Gilead Sciences’ Big Growth Opportunity for 2016 Is HCV
Yahoo/Market Realist
Thu, 05/19/16 - 09:41 am
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Behind Gilead Sciences’ Pricing Pressures for HCV Drugs in the US
Yahoo/Market Realist
Thu, 05/12/16 - 09:47 am
Gilead Sciences
hepatitis C
drug pricing
Harvoni
Sovaldi
Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut
Motley Fool
Mon, 05/9/16 - 10:22 am
Merck
earnings
Zepatier
hepatitis C
'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier
BioPharma Dive
Mon, 05/2/16 - 10:11 am
drug pricing
Merck
hepatitis C
Zepatier
Gilead Judge Re-Opens Case Amid Claim Merck Scientist Lied
Bloomberg
Sat, 04/30/16 - 10:41 am
Gilead Sciences
Merck
hepatitis C
Harvoni
Sovaldi
Seven New York insurers end restrictions on coverage for hepatitis C drugs
BioPharma Dive
Wed, 04/27/16 - 09:20 am
New York
insurers
hepatitis C
Merck
Zepatier
Gilead Sciences
Harvoni

Pages